RE: VRCI undervalued pharma stock by far on FTSE. Target: 20p for me.28 Mar 2025 07:18
Morning, hope to nab a few more sub 3p todaay after closing another position.
I feel soon this will soar as the seller is basically done now.
VRCI has much higher revenues than AGL (Angle), considerably lower costs (VRCI around break even, AGL £12-18m LOSS per annum) and the market cap is £5m for VRCI vs £30m for AGL.
This is due a considerable re-rate from here.